Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer

Dasatinib (DAS) is a multikinase inhibitor that acts on several signaling kinases. DAS is used as a second-line treatment for chronic accelerated myeloid and Philadelphia chromosome-positive acute lymphoblastic leukemia. The therapeutic potential of DAS in other solid tumours is under evaluation. As...

Descripción completa

Detalles Bibliográficos
Autores principales: Niza, Enrique, Noblejas-López, María del Mar, Bravo, Iván, Nieto-Jiménez, Cristina, Castro-Osma, José Antonio, Canales-Vázquez, Jesús, Lara-Sanchez, Agustín, Galán Moya, Eva M., Burgos, Miguel, Ocaña, Alberto, Alonso-Moreno, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955794/
https://www.ncbi.nlm.nih.gov/pubmed/31888247
http://dx.doi.org/10.3390/nano9121793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955794/
https://www.ncbi.nlm.nih.gov/pubmed/31888247
http://dx.doi.org/10.3390/nano9121793

Ejemplares similares